The Furiex Management Team

Furiex has assembled a world-class team of drug development experts, bringing extensive experience across a wide range of therapeutic areas. Our leadership team collectively has more than 75 years of experience. Together, we build value by designing innovative programs that drive development faster and more efficiently across the development timeline.

Management TeamTOP

  • June Almenoff, M.D., Ph.D., FACP

    June Almenoff, M.D., Ph.D., FACP

    President and Chief Medical Officer

    June Almenoff, M.D., Ph.D., is president and chief medical officer, and serves on the board of directors. She is Furiex's principal executive officer. Dr. Almenoff joined Furiex after a successful 12-year career at GlaxoSmithKline, and has served as president and chief medical officer of Furiex since its inception in 2010.

  • Sailash Patel

    Sailash Patel

    Chief Financial Officer and Vice President Strategic Development

    Mr. Patel has served as the company’s Vice President of Strategic Development since 2010. Prior to that, Mr. Patel was the General Manager of BioDuro, a PPD company, where he was responsible for all functional aspects, including P&L accountability, of a 700 employee China-based drug discovery unit, providing integrated discovery services to the pharmaceutical industry.

  • Paul Covington, M.D.

    Paul Covington, M.D.

    Senior Vice President, Clinical Development and Operations

    Dr. Paul Covington brings more than 17 years of drug development experience overseeing all aspects of medical and regulatory affairs including pharmacovigilance, medical writing and program management. Dr. Covington also has experience as a medical practitioner in both hospital and private practice settings.

  • Gail McIntyre, Ph.D., CH (ASCP), DABT

    Gail McIntyre, Ph.D., CH (ASCP), DABT

    Senior Vice President, Research

    Dr. Gail McIntyre has more than 19 years of experience in the drug discovery and development industry at both biotechnology and pharmaceutical companies. She is a board certified toxicologist with extensive experience in moving compounds through the lead optimization phase to IND. Dr. McIntyre led PPD's compound partnering group for six years.